Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis.

Abstract

OBJECTIVE:

To assess the clinical and economic consequences of a formulary switch from enoxaparin to dalteparin as first-line prophylaxis for deep-vein thrombosis in patients undergoing inpatient rehabilitation after total hip arthroplasty or total knee arthroplasty.

DESIGN:

Retrospective cohort study.

RESULTS:

There were 461 patients eligible for the study. The age-adjusted risk of a deep-vein thrombosis event confirmed by duplex ultrasonography among patients treated with dalteparin was substantially lower than among patients treated with enoxaparin, whereas the age-adjusted risk of a bleeding event in the dalteparin group was also lower than that in the enoxaparin group. Adjusted per capita costs of deep-vein thrombosis prophylaxis during the rehabilitation stay were $129 lower among subjects treated with dalteparin.

CONCLUSION:

The switch to dalteparin as a first-line therapy for deep-vein thrombosis prophylaxis in the rehabilitation period after total hip arthroplasty or total knee arthroplasty has led to substantial cost savings for Kessler Institute without compromising patient care.

• Authors: R Krotenberg, U Adler, B Pomeranz, J D Miller, M W Russell
• Journal: American journal of physical medicine & rehabilitation (Am J Phys Med Rehabil) Vol. 80 Issue 12 Pg. 889-95 (Dec 2001) ISSN: 0894-9115 [Print] United States
• PMID: 11821667 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anticoagulants
• Enoxaparin
• Dalteparin

Topics

• Aged
• Anticoagulants (therapeutic use)
• Arthroplasty, Replacement, Hip (economics)
• Arthroplasty, Replacement, Knee (economics)
• Costs and Cost Analysis
• Dalteparin (therapeutic use)
• Enoxaparin (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• New Jersey
• Retrospective Studies
• Venous Thrombosis (economics, prevention & control)